Table 1 Patient Characteristics
All patients | Frontline daratumumab patients | Daratumumab initiated in 2 L | Daratumumab initiated in 3 L+ | Re-treated patients1 | |
|---|---|---|---|---|---|
N = 299 | N = 26 | N = 66 | N = 207 | N = 19 | |
Demographic characteristics | |||||
Age at daratumumab initiation, mean ± SD [median] | 67.7 ± 11.3 [69.0] | 68.2 ± 13.9 [72.0] | 68.4 ± 10.2 [68.0] | 67.4 ± 11.3 [68.0] | 67.2 ± 14.7 [66.0] |
Time between MM diagnosis and daratumumab initiation (months), mean ± SD [median] | 35.4 ± 30.6 [29.6] | 2.1 ± 1.9 [1.8] | 24.2 ± 24.6 [15.1] | 43.2 ± 30.4 [36.7] | 53.3 ± 41.3 [45.3] |
Sex, n (%) | |||||
Male | 164 (54.8) | 15 (57.7) | 36 (54.5) | 113 (54.6) | 10 (52.6) |
Female | 135 (45.2) | 11 (42.3) | 30 (45.5) | 94 (45.4) | 9 (47.4) |
Race, n (%) | |||||
White | 163 (54.5) | 15 (57.7) | 41 (62.1) | 107 (51.7) | 10 (52.6) |
Black or African American | 89 (29.8) | 4 (15.4) | 11 (16.7) | 74 (35.7) | 7 (36.8) |
Hispanic | 6 (2.0) | 0 (0.0) | 2 (3.0) | 4 (1.9) | 0 (0.0) |
Asian | 4 (1.3) | 1 (3.8) | 1 (1.5) | 2 (1.0) | 0 (0.0) |
Mixed | 9 (3.0) | 2 (7.7) | 3 (4.5) | 4 (1.9) | 1 (5.3) |
Other | 1 (0.3) | 0 (0.0) | 1 (1.5) | 0 (0.0) | 0 (0.0) |
Unknown | 27 (9.0) | 4 (15.4) | 7 (10.6) | 16 (7.7) | 1 (5.3) |
Primary insurance plan type, n (%) | |||||
Medicare | 181 (60.5) | 15 (57.7) | 37 (56.1) | 129 (62.3) | 13 (68.4) |
Commercial insurance | 46 (15.4) | 4 (15.4) | 15 (22.7) | 27 (13.0) | 3 (15.8) |
Medicaid | 8 (2.7) | 0 (0.0) | 0 (0.0) | 8 (3.9) | 0 (0.0) |
Other | 35 (11.7) | 1 (3.8) | 7 (10.6) | 27 (13.0) | 1 (5.3) |
Unknown | 29 (9.7) | 6 (23.1) | 7 (10.6) | 16 (7.7) | 2 (10.5) |
Clinical characteristics | |||||
MM stage as of MM diagnosis date (R-ISS)2, n (%) | |||||
Stage I | 58 (19.4) | 8 (30.8) | 17 (25.8) | 33 (15.9) | 1 (5.3) |
Stage II | 104 (34.8) | 8 (30.8) | 26 (39.4) | 70 (33.8) | 4 (21.1) |
Stage III | 58 (19.4) | 2 (7.7) | 9 (13.6) | 47 (22.7) | 5 (26.3) |
Unknown | 79 (26.4) | 8 (30.8) | 14 (21.2) | 57 (27.5) | 9 (47.4) |
Cytogenetic profile as of daratumumab initiation3, n (%) | |||||
Standard | 108 (36.1) | 19 (73.1) | 27 (40.9) | 62 (30.0) | 9 (47.4) |
High | 55 (18.4) | 4 (15.4) | 9 (13.6) | 42 (20.3) | 2 (10.5) |
Unknown | 136 (45.5) | 3 (11.5) | 30 (45.5) | 103 (49.8) | 8 (42.1) |
Refractory disease prior to daratumumab initiation4, n (%) | |||||
To any line of therapy prior to daratumumab initiation | 210 (76.9) | – | 35 (53.0) | 175 (84.5) | 15 (83.3) |
To an immunomodulatory drug | 162 (59.3) | – | 25 (37.9) | 137 (66.2) | 10 (55.6) |
To a proteasome inhibitor | 153 (56.0) | – | 14 (21.2) | 139 (67.1) | 13 (72.2) |
To a proteasome inhibitor and an immunomodulatory drug | 111 (40.7) | – | 7 (10.6) | 104 (50.2) | 8 (44.4) |
Year of daratumumab initiation, n (%) | |||||
2015 | 2 (0.7) | 0 (0.0) | 0 (0.0) | 2 (1.0) | 1 (5.3) |
2016 | 32 (10.7) | 0 (0.0) | 2 (3.0) | 30 (14.5) | 4 (21.1) |
2017 | 55 (18.4) | 0 (0.0) | 10 (15.2) | 45 (21.7) | 4 (21.1) |
2018 | 78 (26.1) | 2 (7.7) | 20 (30.3) | 56 (27.1) | 6 (31.6) |
2019 | 90 (30.1) | 15 (57.7) | 23 (34.8) | 52 (25.1) | 4 (21.1) |
2020 | 42 (14.0) | 9 (34.6) | 11 (16.7) | 22 (10.6) | 0 (0.0) |